metformin has been researched along with Latent Tuberculosis in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Latent Tuberculosis: The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, the effect of the same on latent tuberculosis is still unknown." | 5.62 | Metformin and Rifampicin combination augments active to latent tuberculosis conversion: A computational study. ( Banerjee, D; Bhattacharyya, R; Kaur, S; Yadav, D, 2021) |
| "However, the effect of the same on latent tuberculosis is still unknown." | 1.62 | Metformin and Rifampicin combination augments active to latent tuberculosis conversion: A computational study. ( Banerjee, D; Bhattacharyya, R; Kaur, S; Yadav, D, 2021) |
| " In multivariate analysis, the initial 2-year dosage of metformin, but not that of the sulfonylureas, was an independent predictor of TB (60-cDDD increase (adjusted hazard ratio [HR], 0." | 1.48 | The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. ( Chan, YJ; Chuang, PH; Feng, JY; Kou, YR; Pan, SW; Su, VY; Su, WJ; Yen, YF, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russell, SL | 1 |
| Lamprecht, DA | 1 |
| Mandizvo, T | 1 |
| Jones, TT | 1 |
| Naidoo, V | 1 |
| Addicott, KW | 1 |
| Moodley, C | 1 |
| Ngcobo, B | 1 |
| Crossman, DK | 1 |
| Wells, G | 1 |
| Steyn, AJC | 1 |
| Yadav, D | 1 |
| Kaur, S | 1 |
| Banerjee, D | 1 |
| Bhattacharyya, R | 1 |
| Pan, SW | 1 |
| Yen, YF | 1 |
| Kou, YR | 1 |
| Chuang, PH | 1 |
| Su, VY | 1 |
| Feng, JY | 1 |
| Chan, YJ | 1 |
| Su, WJ | 1 |
| Magee, MJ | 1 |
| Salindri, AD | 1 |
| Kornfeld, H | 1 |
| Singhal, A | 1 |
| Yew, WW | 1 |
| Chang, KC | 1 |
| Chan, DP | 1 |
| Zhang, Y | 1 |
1 review available for metformin and Latent Tuberculosis
| Article | Year |
|---|---|
Metformin as a host-directed therapeutic in tuberculosis: Is there a promise?
Topics: Animals; Antitubercular Agents; Autophagy; Drug Interactions; Drug Therapy, Combination; Forecasting | 2019 |
4 other studies available for metformin and Latent Tuberculosis
| Article | Year |
|---|---|
Compromised Metabolic Reprogramming Is an Early Indicator of CD8
Topics: Animals; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Female; Glycolysis; Hypoglycemic Ag | 2019 |
Metformin and Rifampicin combination augments active to latent tuberculosis conversion: A computational study.
Topics: Antitubercular Agents; Humans; Latent Tuberculosis; Metformin; Microbial Sensitivity Tests; Molecula | 2021 |
The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; | 2018 |
Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins.
Topics: Antibiotics, Antitubercular; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hydroxymeth | 2019 |